Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

NCT07348263 · View on ClinicalTrials.gov ↗

Study Summary

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Conditions Studied

Study Locations (15)

Other

  • Children's Hospital Zagreb — Zagreb
  • Hamburger Zentrum für Kinder- und Jugendrheumatologie - — Hamburg
  • Ruth Rappaport Children's Hospital of Haifa — Haifa
  • IRCCS Giannina Gaslini, — Genova
  • Università di Udine — Udine
  • Iuliu Hatieganu University of Medicine and Pharmacy — Cluj-Napoca
  • University Children's Hospital — Ljubljana
  • Hospital Sant Joan de Déu, — Barcelona
  • Cerrahpasa Medical School, Istanbul University — Istanbul
  • Alder Hey Children's Hospital — Liverpool
  • Great North Children's Hospital, Newcastle Upon Tyne — Newcastle upon Tyne

Alabama

  • University of Alabama at Birmingham — Birmingham

New York

  • SUNY Upstate Pediatric Rheumatology — Syracuse

FI

  • Meyer Children's Hospital IRCCS — Florence

Stockholm County

  • Astrid Lindgren Children's Hospital — Solna

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-05-15
Est. Completion 2027-05-15

Sponsor

Meyer Children's Hospital IRCCS

31 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07348263

The ClinicalTrials.gov registry entry for NCT07348263 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meyer Children's Hospital IRCCS, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Eosinophilic Fasciitis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07348263 reports 15 study locations spanning 5 distinct geographic areas — top geographies include Other, Alabama, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07348263 about?

NCT07348263 is a clinical study titled "EFESO: Study on Juvenile Onset Eosinophilic Fasciitis". Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represent...

What is the current status of trial NCT07348263?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-05-15. Estimated completion is 2027-05-15.

What conditions does trial NCT07348263 study?

This clinical trial studies the following conditions: Eosinophilic Fasciitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT07348263?

This trial is sponsored by Meyer Children's Hospital IRCCS, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07348263 being conducted?

This trial has 15 study locations across Alabama, New York, FI, Stockholm County. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial